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OBJECTIVES: To examine the factors associated with total health care expendi-
tures in newly diagnosed subjects with colorectal cancer (CRC) receiving systemic
therapy. METHODS: Patients ages 18-63 years when newly diagnosed with CRC
between January 1, 2005 and June 31, 2009 receiving systemic therapy were iden-
tified using a large, US-based administrative medical claims (MarketScan) data-
base. At least 6 months of patient history prior to CRC diagnosis and at least 1-year
post-index continuous enrollment was required. Patients were followed from ini-
tial CRC diagnosis (index date) to disenrollment or June 31, 2010. Chemotherapy
and biologic treatments over time were analyzed to identify lines of therapy. Gen-
eralized linear regressionmodelswere used to estimate totalmedical expenditures
(outcome variable) as a function of number of lines of therapy (key independent
variable) and demographic/clinical covariates. The excess expenditures associated
with additional lines of therapy were estimated as the difference between pre-
dicted medical expenditures for those with 1st line of therapy versus 2nd and 3rd 
lines of therapy. RESULTS:A total of 5160 subjects were includedwith themajority
being male (55%) and between ages 51-60 years (52%). After adjusting for demo-
graphic, and clinical covariates (comorbidities, metastasis development, and post-
index CRC surgery and radiation) and follow-up days, the mean annualized total
health care costs (N5,160) were predicted to be $67,902. Use of 2nd line and 3rd line
 therapies was associated with an annualized incremental costs of $11,662 [95%
confidence interval (CI): $8,581-$14,876] and $43,313 (95% CI: $43,313-$49,401), re-
spectively. Age, gender, region, index year of diagnosis, post-index CRC surgery
and/or radiation, development of metastasis (p-value0.0001), presence of vascu-
lar comorbidities (p-value0.02), plan type (p-value0.04) and use of first line be-
vacizumab (p-value0.0002) were all associated with statistically significant in-
creased likelihood of costs. CONCLUSIONS: Additional lines of therapy and use of
first line biologics increased the cost of treatment substantially in CRC patients.
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OBJECTIVES: In the Brazilian private healthcare system, coverage for oral therapy
is not mandatory. The association of lapatinib and capecitabine (LAP/CAP), both
orally administered, is an effective combination for the treatment of patients with
metastatic HER2 positive breast cancer (MBC-HER2) after progression to trastu-
zumab, but is not frequently used. The objective of this study was to evaluate
treatment patterns and associated costs of MBC-HER2 after progression to tras-
tuzumab, under the perspective of the Brazilian private healthcare system and to
calculate the economic impact associated with using LAP/CAP for this population.
METHODS: Evidencias® database contains data related to around 3,000,000 lives
covered by private health plans in Brazil. In this database, patients diagnosed with
MBC-HER2 and treated with chemotherapy after failure to trastuzumab were
selected. For every patient, treatment costs were calculated considering drug costs
only. Three cost scenarios were estimated: i) real-life chemotherapy (CT) used by
patients; ii) hypothetical use of LAP/CAP; iii) hypothetical use of trastuzumab as-
sociated to capecitabine (TRAST/CAP). RESULTS: A total of 182 patients were in-
cluded in the analysis. Average treatment duration was 10.5 weeks (95% CI: 8.9 -
12.2). Twenty-two treatment protocols were identified after failure to trastuzumab,
mainly: paclitaxel (27%), docetaxel (20%) and vinorelbine (14%). The average cost
per patient were R$19,114.68, R$25,977.61 and R$39,437.26, in the CT, and projected
LAP/CAP and TRAST/CAP scenarios, respectively. Considering the results seg-
mented by CT protocol, LAP/CAP costswere lower than CT for patients treatedwith
paclitaxel associated or not to gemcitabine, among others. For all patients, pro-
jected costs with LAP/CAP were lower than TRAST/CAP. CONCLUSIONS: Patients
treated with CT, eligible for treatment with LAP/CAP or TRAST/CAP, had lower
treatment costs when compared to LAP/CAP or TRAST/CAP. In some specific CT
combinations, however, LAP/CAP may result in lower costs, thus being considered
an economically viable alternative.
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OBJECTIVES: In 2004, average Medicare payments for treating squamous cell head
andneck cancer (SCCHN)were an estimated $25,000 higher thanmatched controls.
Specific diagnostic, treatment and end-of-life cost have not been delineated nor
have the cost of newer biologic agents been factored into these estimates. We aim
to determine the costs of diagnostic, treatment, and end-of-life phases of SCCHN
and overall cost of treatment prior to and following cetuximab approval.
METHODS: This was a retrospective analysis of the PharMetrics Choice insurance
claims database. Patients 20 years of age with ICD-9-CM codes suggestive of
advanced SCCHN diagnosed between March 1, 2003 and March 1, 2008 were in-
cluded. Patients were divided by date of diagnosis prior to or following cetuximab
approval (3/1/2006). Direct medical costs were calculated for specific phases (i.e.,
diagnostic, treatment, end-of-life) and overall. Patient characteristics are pre-
sented as descriptive statistics. Medical costs between phases and cohorts were
compared using the Mann-Whitney U-Test. RESULTS: Overall, 366 patients met
study criteria. Patients were predominately male (78.4%) with a median age of 57
years. Diagnostic costswere lower in pre-cetuximab ($5053) versus post-cetuximab
($6860) cohorts (p0.028). Costs of treatment ($102,427 vs. $97,594; p0.69) and
end-of-life ($15,853 vs. $21,822; p0.57) were similar among cohorts. Median total
costs for pre- and post-cetuximab cohorts were $110,099 and $111,156, respectively
(p0.82). Treatment costs comprised the greatest percentage of total cost (89.3%)
for SCCHN. Outpatient costs were the primary driver of treatment costs (median
$19,248; 23%) followed by radiation therapy (median $15,691; 18%). Chemotherapy
accounted for 2.6% (median $974) of treatment costs. In the post-cetuximab cohort,
cetuximab was responsible for 5.7% and 4.4% of total and treatment costs,
respectively. CONCLUSIONS: Compared to diagnosis and end-of-life phases, treat-
ment is the primary driver of SCCHNcosts, predominated by outpatient costs. Total
costs were similar prior to and following cetuximab approval.
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OBJECTIVES: Autologous hematopoietic stem cell transplantation is considered to
be standard care for patientswithMMandNHL. For patients to proceed to stem cell
transplantation, a sufficient number of stem cells must first be harvested through
an apheresis procedure. Therapies such as plerixafor and filgrastim are used to
enhance stem cellmobilization in these patients. The cost of apheresis, however, is
difficult to obtain in a hospital setting in the Canadian context. METHODS: The
main resource components for apheresis includes materials (plasma exchange
sets, administration materials), medication, central line insertion, albumin 4% so-
lution, laboratory tests, cryopreservation, nursing time and physician visits. Based
on interviews conducted from a sample of nurses in the plasma exchange unit of
University Health Network in Toronto, resource utilization was estimated.
RESULTS: Costing for apheresis was done for a 4-day treatment protocol with
different resource requirements for initial and subsequent sessions. It was deter-
mined that total costs of apheresis use for the first day and the subsequent 3 days
were variable. It was estimated that over a four day treatment protocol, costs for
materials, medication, central line insertion, albumin 4% solution, laboratory tests
and nursing time amounted to $6035 (95% CI: $5291-$6780). The costs for the first
session was estimated to be $1671 (95% CI: $$1,803-$1431). In addition, cyroprese-
vation and storage costs of stem-cellswere estimted to be $100 per day (UHN). Total
costs therefore amounted to $6435per 4-day treatment protocol. CONCLUSIONS:
This pilot study provides a reasonable estimate of resource utilization and costs
incurred by hospitals in providing apheresis in Canada.
PCN51
COMPARING THE USE AND COST OF RADIOPHARMACEUTICALS IN PROSTATE
CANCER PATIENTS WITH AND WITHOUT BONE METASTASIS
Seal B1, Sullivan SD2, Ramsey S3, Asche CV4, Shermock K5, Sarma S6, Farrelly E7,
Eaddy M7
1Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 2University of Washington,
Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle,
WA, USA, 4University of Illinois College of Medicine, Peoria, IL, USA, 5Analysis by Design LLC,
Columbia, MD, USA, 6Independent Consultant, Wilmington, NC, USA, 7Xcenda, Palm Harbor, FL,
USA
OBJECTIVES: The use of radiopharmaceuticals in oncology is expected to increase
over the next few years. There are few studies, however, describing the cost asso-
ciated with their use. This analysis compared the utilization and cost of patients
treated in an outpatient or inpatient setting for prostate cancer (PCa) with bone
metastasis (wBM) to those without bone metastasis (w/oBM). METHODS: Patients
in the Premier Hospital Database between January 2006 andDecember 2010 treated
in an inpatient or outpatient setting for PCa (ICD9 Codes 185 and 233.4) were in-
cluded. Patients were required to be 40 years of age with no additional cancers.
Patientswere put into cohorts based on the presence of bonemetastasis (ICD9 code
198.5 or the use of zoledronic acid or pamidronate disodium). Utilization of radio-
pharmaceuticals and PCa-specific treatments were compared, controlling for age,
race, hospital, provider payer types, bed size, and admission source and type. Dif-
ferences in treatments were assessed utilizing logistic regression, while differ-
ences in costs were analyzed using gamma distributed generalized linear models
with a log link function.RESULTS:Therewere 23,747 hospitalizations formenwBM
and 187,708 hospitalizations for men w/oBM. The mean age of men wBM was 73
years compared to 69 years for men w/oBM. The use of nuclear medicine-related
PCa treatmentswas higher in patientsw/oBM (4.8%) compared towBM (1.2%).With
overall costs of $9,728 in men with wBM and $7,405 (p0.0006) in those w/oBM,
nuclear medicine contributed only 1.2% and 5.2%, respectively (p0.0001). Room
and board contributed the greatest proportion of costs in men wBM (38.9%), while
surgery (24.2%), room and board, and radiation (20% each) were the major con-
tributors in men w/oBM. CONCLUSIONS: Although increasing in use, currently
radiopharmaceuticals do not significantly contribute to the total cost of treating
PCa patients in an inpatient or outpatient setting.
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